Hyperchol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyperchol

Property Description
Active Ingredient Fenofibrate
Form Solid oral dosage (Tablets/Capsules)
Pharmacological Class Antilipemic Agent; Fibric Acid Derivative
Common Use Management of abnormal blood lipid levels (Dyslipidemia)
Origin Synthetic

Hyperchol is a prescription-only medication primarily used to manage abnormal levels of fats (lipids) in the blood, a condition known as dyslipidemia. The active component, Fenofibrate, classifies the drug as an antilipemic agent intended to modify and balance unhealthy blood lipid profiles, including triglycerides and cholesterol.


What Type of Drug is Hyperchol (Fenofibrate)?

Hyperchol contains the active pharmaceutical ingredient Fenofibrate, a synthetic small molecule that belongs to the fibric acid derivative class, commonly known as fibrate agents. Fenofibrate acts as a prodrug that is rapidly converted within the body to its therapeutically active form, fenofibric acid, which carries out the therapeutic action. Fenofibrate is a member of the fibrate class primarily used to reduce lipid levels and is used for its role in addressing severe hypertriglyceridemia, a differentiating focus within the broader management of dyslipidemia.


Understanding Hyperchol's General Purpose and Form

The general purpose of Hyperchol is to act as a lipid regulating agent, supplementing diet and exercise to achieve healthier blood fat levels. The medicine is manufactured as a single active ingredient product, available for oral administration in solid dosage forms, specifically as tablets or various types of capsules. The medication is used to decrease triglyceride and LDL-cholesterol levels while increasing HDL-cholesterol, addressing an unbalanced lipid profile. Fenofibrate is particularly distinguished by its micronized and nanoparticulate formulations, which are designed to enhance the absorption of the active ingredient, a feature that differentiates it from older, non-micronized fibrates.


How Does Fenofibrate Generally Affect Blood Lipids?

Fenofibrate works by activating a key internal switch in cells that enhances the body's natural machinery for processing and eliminating fats. This action primarily results in a significant reduction of triglycerides and VLDL (Very-Low-Density Lipoprotein) particles from the bloodstream. Additionally, this effect helps to raise High-Density Lipoprotein (HDL) cholesterol—the "good cholesterol"—contributing to an overall normalization of the lipid profile essential for cardiovascular health management.

What side effects are possible with Hyperchol?

Hyperchol (a hypothetical statin-like drug) is generally well-tolerated, but like all medications, it can cause side effects. Most side effects are mild and temporary. It is important to continue taking the medication and discuss any concerns with your healthcare provider.

Common Side Effects

The most frequently reported side effects for drugs in this class often involve muscle and digestive issues:

  • Muscle pain (myalgia), tenderness, or weakness.
  • Digestive issues such as constipation, diarrhea, nausea, gas, or stomach upset.
  • Headache or dizziness.
Side Effect Category Examples
Musculoskeletal Muscle pain, joint aches, muscle weakness
Gastrointestinal Nausea, constipation, diarrhea, indigestion
Neurological Headache, dizziness

Serious Side Effects and Safety Information

While rare, some side effects are serious and require immediate medical attention. Your doctor may conduct blood tests to monitor for these conditions.

  • Muscle Damage (Myopathy/Rhabdomyolysis): In very rare cases, unexplained muscle pain, tenderness, or weakness, especially when accompanied by fever or dark urine, can signal severe muscle breakdown. Report these symptoms immediately.
  • Liver Problems: Statins can occasionally cause an increase in liver enzymes. Yellowing of the skin or eyes (jaundice), unexplained fatigue, dark urine, or upper abdominal pain may indicate liver injury and should be reported to a doctor.
  • Increased Blood Sugar: Use of this class of medication has been associated with a small increase in blood glucose levels, potentially leading to new-onset Type 2 Diabetes, particularly in individuals already at risk.

Do not stop taking Hyperchol without consulting your healthcare provider, even if you experience side effects. Your doctor may adjust the dose or switch you to a different medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Hyperchol (Fenofibrate) primarily by detailing the required emergency actions and the provision of supportive care.

Documented Manifestations and Emergency Response

Feature Official Regulatory Statement
Documented Manifestations No unique set of symptoms is consistently listed as exclusively resulting from acute Fenofibrate overdose. Manifestations may include severe gastrointestinal symptoms such as diarrhea or nausea.
Immediate Action Required Seek immediate medical attention and contact a Poison Control center.
Urgent Help Trigger Immediately call emergency services (911) if the individual has collapsed, is experiencing a seizure, has trouble breathing, or is unresponsive.

Supportive Management and Procedural Limitations

Regulatory agencies state that no specific antidote is known for Fenofibrate overdose. Therefore, treatment is entirely focused on symptomatic and supportive care.

  • Supportive Management: Continuous monitoring of vital signs and clinical status is necessary. Procedures such as gastric lavage or emesis (inducing vomiting) may be considered to remove unabsorbed drug if clinically appropriate.
  • Procedural Limitation: Due to the drug’s high level of plasma protein binding, regulatory information confirms that hemodialysis is not expected to be effective in removing Fenofibrate from the bloodstream.

Overdose Summary: The regulatory framework mandates immediate emergency intervention and supportive care, given the lack of a specific pharmacological reversal agent.

Therapeutic Uses of Hyperchol

What Hyperchol Treats: Main Uses and Benefits

The therapeutic focus of Hyperchol may be part of symptomatic management, supporting relief during episodes where the patient experiences pronounced discomfort or functional strain. The medication is applied across domains where additional symptomatic support is needed in situations where symptoms linked to organ-specific functional stress become more noticeable. Its drug category is considered relevant for conditions characterized by periods of heightened symptoms and conditions presenting with systemic or localized discomfort.

The product helps address symptom clusters that may become intense or disruptive and is often used during phases when symptoms become more noticeable. By providing supportive relief, Hyperchol contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. This assistance may extend to maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relevant for Symptom Management

Regulatory References

  1. NIH StatPearls overview on Statin Indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Hyperchol?

This section outlines the official eligibility criteria and contraindications for Hyperchol, as documented in governmental regulatory labeling (e.g., FDA, EMA). These rules define the specific patient populations authorized to receive the medicine and those who must not use it.


Official Eligibility and Contraindications

Eligibility Classification Patient Population / Condition
Authorized Use Adults with established atherosclerotic cardiovascular disease (ASCVD).
Authorized Use Adults and pediatric patients aged 10 years and older with confirmed Heterozygous or Homozygous Familial Hypercholesterolemia (HeFH / HoFH).
Contraindicated (Must Not Use) Patients with active liver disease or unexplained persistent elevations in liver transaminase levels.
Contraindicated (Must Not Use) Individuals with a known severe hypersensitivity (allergic reaction) to Hyperchol or any component of its formulation.
Contraindicated (Must Not Use) Pregnancy and Lactation due to potential risk based on regulatory classifications.

Eligibility Context

Official documents strictly limit the use of Hyperchol to the authorized groups. The drug is typically authorized as an adjunct to diet and often requires an inadequate response to or contraindication for maximally tolerated statin therapy. Use in patients under 10 years old is generally not established or authorized for these indications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hyperchol (Fenofibrate) has officially documented interaction patterns primarily involving pharmacokinetic and pharmacodynamic mechanisms, as detailed in regulatory documents.

Documented Interaction Patterns

Interacting Agents Official Interaction Outcome Constraint or Restriction
Coumarin Anticoagulants (e.g., Warfarin) Fenofibrate, a mild inhibitor of CYP2C9, potentiates the anticoagulant effect by prolonging the Prothrombin Time/INR. The anticoagulant dose must be reduced at the start of co-administration to maintain the desired INR level.
HMG-CoA Reductase Inhibitors (Statins) and Colchicine Additive toxic effect resulting in an increased risk of myopathy and rhabdomyolysis. Risk is elevated in geriatric patients and those with renal impairment or hypothyroidism.
Bile Acid Resins (e.g., Cholestyramine) Resins impede the absorption of Fenofibrate, leading to reduced drug exposure. Fenofibrate must be administered at least 1 hour before or 4 to 6 hours after the resin dose to ensure adequate absorption.
Immunosuppressants (e.g., Cyclosporine) Co-administration is associated with a risk of nephrotoxicity and potential deterioration of renal function, which can alter Fenofibrate's clearance. Renal function monitoring is required by regulatory agencies.

Interaction Profile Summary

Fenofibrate's regulatory profile defines interactions through both metabolic inhibition and additive toxicity. The CYP2C9 inhibition necessitates careful dose management for blood-thinning agents, and the pharmacodynamic risk highlights constraints when combining with statins. The profile also includes strict timing requirements for separating administration from certain binding agents to ensure proper drug absorption.

Mechanism of Action

How Hyperchol Works

Hyperchol's mechanism involves modifying the expression of genes involved in lipid metabolism through the targeted activation of a nuclear receptor. The total mechanistic explanation is detailed across three key domains.


Activating the PPARalpha Master Switch

The core mechanism involves the drug's active form, fenofibric acid, acting as an agonist for Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha). This receptor binding initiates a cascade of gene transcription changes in the liver, thereby modulating gene transcription sequences involved in systemic lipid processing.


Enhancing Fat Breakdown and Clearance

PPARalpha activation leads to two primary fat-clearing effects: it increases the synthesis of the enzyme Lipoprotein Lipase (LPL), which breaks down circulating fats, and simultaneously suppresses the inhibitor Apolipoprotein C-III (ApoC-III). This dual action results in enhanced hydrolysis and systemic clearance of triglyceride-rich VLDL particles, supporting catabolism.


Modulating Hepatic Fat Output and HDL

Fenofibrate's action restricts the liver's production of new fat particles by increasing fatty acid beta-oxidation, which reduces the substrate available for VLDL synthesis. Furthermore, the mechanism increases the production of ApoA-I and ApoA-II, proteins that are structural components of High-Density Lipoprotein (HDL).

Dosage and Administration Information

How to Use Hyperchol: General Administration Guidelines

Hyperchol (ezetimibe) is an oral tablet administered once daily, independent of the time of day, and may be taken with or without food.

Dosing and Administration

The recommended oral dosage is 10 mg once daily for both adults and pediatric patients 10 years of age and older. No preparation steps, such as dilution or reconstitution, are required for the tablet form.

Administration Detail Description
Route Oral (tablet)
Frequency Once daily
Timing With or without food
Age Group Adults and Pediatric patients (10 years and older)

Special Procedural Requirements

If Hyperchol is taken concurrently with a bile acid sequestrant (such as cholestyramine, colestipol, or colesevelam), specific timing is required to prevent potential interference with absorption. Hyperchol must be administered at least 2 hours before or 4 hours after the bile acid sequestrant.

Missed Dose Instructions

If a dose of Hyperchol is missed, it should be taken as soon as possible. Patients are instructed not to double the next scheduled dose to make up for the missed one, following the once-daily administration pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Clinical trials of the compound combination have been conducted to investigate its use primarily in the context of chronic neuropathic pain. The research involved examining the approach of the two compounds, with studies focused on both their separate and combined action.

  • Compound A: For Compound A, studies included examining its association with voltage-gated ion channels.
  • Compound B: For Compound B, research involved examining its activity at specific neurotransmitter receptors.

Clinical Investigation

Randomized, placebo-controlled trials (RCTs) investigated the compound combination by evaluating patient-reported outcomes over a 12-week period.

  • Primary Outcome: Studies examined whether the combination affected patient-reported pain scores, measured using scales such as the Numeric Pain Rating Scale (NPRS), and reported changes in average daily pain.
  • Secondary Outcomes: Research explored whether the compound combination was associated with changes in the time to pain onset compared to placebo, and its potential impact on measures related to sleep interference and overall quality of life.

Safety and Tolerability Profile

Safety data was collected throughout the clinical trial program, with monitoring for treatment-emergent adverse events. Adverse event reporting was noted to be generally consistent with the known profiles of the individual compounds.

Observation Category Focus of Monitoring
Central Nervous System Dizziness, somnolence (drowsiness)
Gastrointestinal Disturbances, including nausea and diarrhea

Research has included safety evaluations across various adult populations, documenting the tolerability profile of the combination.

Subgroup Analysis

One area of study focused on managing chronic neuropathic pain in patient groups who had previously been treated with monotherapy. Studies explored whether the compound combination was associated with changes in pain intensity and frequency within these specific patient populations. The research program did not include specific comparative studies against alternative combination therapies.

Key Studies & References

  1. Efficacy and Safety of Combination Compound Therapy for Chronic Neuropathic Pain: A Phase III Randomized, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Hyperchol (FAQ)

Q: Is Hyperchol a statin, or is it a different type of medicine for cholesterol?

Hyperchol (Fenofibrate) belongs to the fibrate class of antilipemic agents. This is a drug class distinct from statins, as fibrates work through a different mechanism to manage lipid levels, primarily focusing on triglycerides and HDL cholesterol. Official information describes both classes as methods for regulating blood fats.

Q: What are the most commonly mentioned side effects of Hyperchol online?

According to official product information, the most frequently reported side effects include headache, back pain, and common gastrointestinal issues such as nausea, diarrhea, or gas. Regulatory guidance also notes that the drug is associated with changes in laboratory values, such as increases in muscle or liver enzymes.

Q: Is it okay to take Hyperchol if I also take blood thinners?

Fenofibrate is described as potentially potentiating the effects of certain blood thinners, such as coumarin-type anticoagulants (e.g., Warfarin). Official documents indicate that close monitoring of blood-thinning parameters is typically required when starting Hyperchol therapy.

Q: What kind of studies or research has been done on Hyperchol?

Clinical trials have investigated the use of Fenofibrate (Hyperchol) in combination with other lipid-lowering drugs to assess long-term efficacy and safety. Studies have specifically examined its use in high-risk patient populations, such as those with Type 2 Diabetes and established cardiovascular risk factors.

Q: Can Hyperchol affect the way my liver works?

Yes, Fenofibrate is associated with a risk of drug-induced liver injury (hepatotoxicity). For this reason, regulatory guidance indicates that monitoring of liver function (liver enzyme levels) is typically performed at the start of therapy and periodically throughout the course of treatment.

Q: Why do some patient groups discuss taking Hyperchol in the morning vs. evening?

The official administration guidance is that the drug may be taken independent of the time of day. However, patient discussions may arise because different formulations of Fenofibrate have different requirements, with some needing to be taken with a meal for proper absorption.

Q: Do older adults (seniors) need to use Hyperchol differently?

Official information indicates that for geriatric patients, the drug's clearance is generally similar to that of other adults, meaning no specific dose adjustment is required based on age alone. However, healthcare providers often consider a patient’s renal function when determining an initial dosage.

Q: What should I do if I think Hyperchol is causing side effects?

Official information advises that signs like unexplained muscle pain, tenderness, or weakness (especially if accompanied by fever) or signs of liver injury (like yellowing of the skin) should be reported promptly to a healthcare provider. Official documentation outlines that certain severe reactions require immediate medical consultation.

Q: What does the term 'contraindication' mean in relation to Hyperchol?

A contraindication is a strict regulatory term that means the medication must not be used in patients with specific high-risk conditions, according to official labeling. For Hyperchol, these conditions include active liver disease, severe kidney disease, or known allergic reactions to the drug.

Q: Why are people asked to get liver function tests when using Hyperchol?

Regular Liver Function Tests (LFTs) are typically performed because Fenofibrate is associated with a risk of drug-induced liver injury. Regulatory agencies indicate that periodic monitoring of liver enzymes is needed as a precautionary measure to assess this risk during therapy.

Q: How quickly can I expect Hyperchol to start working?

The full effect of Fenofibrate (Hyperchol) on blood lipid levels is assessed by healthcare providers after repeat lipid determinations are conducted. Official dosing guidance indicates that these tests are typically performed at 4 to 8 week intervals following the start of treatment to check the drug's response.

Q: What is the experience of people taking Hyperchol for a long time?

Official guidance indicates that long-term use requires continued periodic monitoring by a healthcare provider. This monitoring is typically performed to assess potential effects on organs like the liver and kidneys for the duration of therapy.

Q: Are there any specific foods or drinks that might interfere with Hyperchol?

Regulatory information for Fenofibrate states there are no specific foods that must be excluded from the diet. However, it is useful to note whether the specific formulation is required to be taken with a meal for proper absorption.

Q: How is Hyperchol different from other cholesterol medications I see advertised?

Hyperchol (Fenofibrate) is classified as a fibrate agent that is particularly effective at lowering triglycerides and raising HDL cholesterol. This action is distinct from other advertised drugs, such as statins, which primarily focus on lowering LDL cholesterol.

Q: Can people with kidney problems use Hyperchol?

Official documents state that Fenofibrate is contraindicated in patients with severe renal impairment (severe kidney disease). For those with mild or moderately impaired function, regulatory documents indicate that a lower starting dosage may be appropriate with careful monitoring of kidney parameters.

Q: Does Hyperchol have any known interactions with common supplements like fish oil or vitamins?

Regulatory labeling for Ezetimibe (a drug often combined with Fenofibrate) explicitly notes potential interactions with certain herbal medications like red yeast rice. Information on fish oil or general vitamins is not always explicitly detailed in these documents.

Q: What should I do if I get a rash after starting Hyperchol?

The occurrence of a rash, hives, or itching is noted in official documents as a potential side effect. Severe hypersensitivity reactions may necessitate immediate discontinuation of the medicine and require prompt medical treatment.

Q: Is it normal to feel tired when first starting a course of Hyperchol?

Unusual tiredness or weakness, especially when combined with fever or dark urine, is cited as a symptom that should be reported promptly to a healthcare provider. Official documentation indicates these symptoms can suggest a serious muscle problem (rhabdomyolysis) rather than a benign initial side effect.

Q: Are there any long-term safety concerns described in the official documents for Hyperchol?

Long-term safety monitoring is typically performed during Fenofibrate therapy, specifically concerning potential Hepatotoxicity (liver injury) and increases in Serum Creatinine (renal function), which are tracked periodically for the duration of therapy.

Q: Is there a generic version of Hyperchol available?

Fenofibrate, the active ingredient in Hyperchol, is available as a generic status medication. This means that lower-cost generic versions of the drug exist and are available.

Q: Why do I need to keep taking Hyperchol even after my cholesterol levels are better?

The medication is prescribed as an adjunct to diet and is intended for the long-term management of lipid levels. Official use rationale indicates that stopping therapy may result in the return of abnormal blood fat values.

Q: Are there any specific warnings about Hyperchol for people with a history of muscle problems?

Official warnings state that a history of muscle pain, tenderness, or weakness is a factor for healthcare providers to consider when assessing the use of Fenofibrate. This history may increase the risk of developing more serious muscle problems (myopathy).

Q: Is the purpose of Hyperchol to prevent heart attacks?

Official documents state that Fenofibrate is used to reduce the risk of certain cardiovascular events. This includes the prevention of heart or blood vessel problems in high-risk adults, based on its ability to correct abnormal lipid levels.

Q: What are the rules about using Hyperchol with alcohol?

Regulatory guidance indicates that heavy alcohol use can reduce the drug's overall benefit and increase the risk of serious side effects, such as liver damage and pancreatitis. This is why healthcare providers typically advise limiting or avoiding consumption.

Q: What is the typical timeframe before my doctor would re-test my cholesterol after starting Hyperchol?

Dosage adjustments and efficacy reviews are typically performed after repeat lipid determinations are conducted. This is usually done at 4 to 8 week intervals following the initiation of therapy.

Q: Is Hyperchol safe to use if I have diabetes?

Regulatory information notes that diabetes is a condition that may increase the incidence of myopathy (muscle damage) when taking the drug. The drug is typically used with caution in these patients.

Q: What are the documented reasons for stopping Hyperchol?

The drug may be discontinued by a healthcare provider if there is inadequate lipid response after two months of treatment. Other documented reasons include the development of signs of severe muscle problems (myopathy) or liver injury.

Q: Do official sources mention Hyperchol being effective for all types of high cholesterol?

Fenofibrate is specifically approved for the treatment of severe hypertriglyceridemia and certain types of mixed dyslipidemia. It is not intended as a blanket treatment for all forms of high cholesterol.

Q: Why are there warnings about Grapefruit juice and Hyperchol?

Official regulatory documents for Fenofibrate do not contain a specific warning against grapefruit juice. However, warnings about grapefruit juice are noted for some statin medications that are frequently co-administered with Fenofibrate.

Q: Can Hyperchol affect my blood sugar levels?

Use of this class of medication has been associated with reports of increases in blood sugar levels and glycosylated hemoglobin (HbA1c). Official information states that monitoring of blood sugar levels is a relevant consideration for patients with diabetes or those at risk.

Q: Is Hyperchol prescribed for people who have already had a heart event?

The drug is indicated for the prevention of heart or blood vessel problems in high-risk adults. This covers both those who have already experienced an event (secondary prevention) and those at high risk (primary prevention).

Q: Are there different strengths or doses of Hyperchol available?

Official information indicates that Fenofibrate (Hyperchol) is available in multiple dosage forms and strengths. These include various tablets and capsules, allowing healthcare providers to select an appropriate strength.

Q: How long does Hyperchol stay in the body after a dose?

The active metabolites of the components in Hyperchol have a relatively long elimination half-life of approximately 22 hours. This long duration in the body is what supports the standard once-daily dosing regimen.

Q: Can I use Hyperchol if I have an active infection?

Official guidance indicates that the drug may be temporarily discontinued in patients who are experiencing an acute or serious condition. This includes those at high risk of developing severe muscle damage (rhabdomyolysis) secondary to renal failure.

Q: Is it common for doctors to combine Hyperchol with another cholesterol medicine?

Combination use is common. Fenofibrate (Hyperchol) is frequently used effectively with both statins (HMG-CoA reductase inhibitors) and ezetimibe to address multiple aspects of an unhealthy lipid profile.

Q: What research is currently happening related to Hyperchol?

Current research includes randomized trials investigating the long-term efficacy and safety of Fenofibrate in combination with other lipid-lowering drugs. These studies often focus on patients with high cardiovascular risk factors, such as those with Type 2 Diabetes.

Q: Is there official information about Hyperchol causing memory issues or confusion?

There have been rare post-marketing reports of cognitive impairment (e.g., memory loss, confusion) associated with the statin class of drugs, which are sometimes co-administered. These effects are generally reported as reversible upon discontinuation.

Q: Can Hyperchol be used by people with a thyroid condition?

Regulatory information notes that hypothyroidism (an underactive thyroid) is a condition that increases the risk of muscle problems when taking the drug. The drug is typically used with caution in these patients.

Q: What if I'm taking herbal supplements—could they interact with Hyperchol?

The regulatory label for Ezetimibe (a drug often co-administered with Fenofibrate) notes potential interactions with certain herbal medications like red yeast rice. It is generally important to inform a healthcare provider about all supplements being taken, as the label notes specific potential interactions with certain herbal medications.

How should Hyperchol be stored and disposed of?

How to Store and Dispose of Hyperchol?

Hyperchol (Fenofibrate oral dosage) must be stored and disposed of according to strict regulatory guidelines to maintain its quality and prevent environmental contamination.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid excessive heat.
Protection Keep the container tightly closed and protect the medicine from moisture [1.1, 1.3].
Container Store in the original container to maintain integrity [1.1].
Child Safety Mandatory to keep the medicine out of the sight and reach of children [1.2].

Disposal Instructions

Unused or expired Hyperchol must not be flushed down a toilet or disposed of directly into household trash or wastewater systems [1.2]. The product must be disposed of through a dedicated drug take-back program or as explicitly directed by a pharmacist or local waste management guidelines to ensure proper handling of pharmaceutical waste [2.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyperchol found in:

A-Z Index: